India Biosimilar Market Report 2024-2032, Industry Trends, Segmentation and Forecast Analysis

Biosimilar Market- India

Base Year: 2023

Historical Years: 2018-2023

Forecast Years: 2024-2032

Market Growth Rate: 18.10% (2024-2032)

The India biosimilar market is growing rapidly, driven by increasing demand for affordable biologic therapies and government support. According to the latest report by IMARC Group, the market is projected to grow at a CAGR of 18.10% from 2024 to 2032.

India Biosimilar Market Trends and Drivers:

1. Rising Prevalence of Chronic Diseases

• Increasing cases of cancer, diabetes, and autoimmune disorders are driving demand for biologic treatments.

2. Cost-Effective Alternative to Original Biologics

• High costs of original biologics create a demand for affordable biosimilars, improving access to advanced therapies.

3. Government Initiatives to Improve Healthcare Access

• Supportive policies and adoption of biosimilars in public healthcare programs are fueling market growth.

4. Expiration of Biologic Patents

• Patents of blockbuster biologic drugs expiring creates opportunities for Indian companies to develop biosimilars.

5. Advancements in Biotechnological R&D

• Biotechnological innovations lead to high-quality, cost-effective biosimilars that are increasingly competitive in the market.

6. Increased Investment and Strategic Partnerships

• Indian pharmaceutical firms are heavily investing in R&D and collaborating with global players to expand their biosimilar portfolios.

7. Growing Acceptance by Healthcare Professionals and Patients

• Increased awareness and confidence in the safety and efficacy of biosimilars are promoting their adoption.

8. Streamlined Regulatory Approval Processes

• Regulatory bodies in India are simplifying approval procedures to encourage the development and commercialization of biosimilars.

9. Market Growth and Global Competitiveness

• As demand for affordable biologic therapies grows, India’s biosimilar market is poised for rapid expansion, positioning the country as a key global competitor.

India Biosimilar Market Industry Segmentation:

The market report offers a comprehensive analysis of the segments, highlighting those with the largest India biosimilar market report. It includes forecasts for the period 2024-2032 and historical data from 2018-2023 for the following segments.

Breakup by Molecule:

• Infliximab
• Insulin Glargine
• Epoetin Alfa
• Etanercept
• Filgrastim
• Somatropin
• Rituximab
• Follitropin Alfa
• Adalimumab
• Pegfilgrastim
• Trastuzumab
• Bevacizumab
• Others

Breakup by Indication Insights:

• Auto-Immune Diseases
• Blood Disorder
• Diabetes
• Oncology
• Growth Deficiency
• Female Infertility
• Others

Breakup by Manufacturing Type:

• In-house Manufacturing
• Contract Manufacturing

Breakup by Region:

• North India
• West and Central India
• South India
• East and Northeast India

Competitive Landscape:

The report offers an in-depth examination of the competitive landscape. It includes a thorough competitive analysis encompassing market structure, key player positioning, leading strategies for success, a competitive dashboard, and a company evaluation quadrant.

Key highlights of the Report:

• Market Performance (2018-2023)
• Market Outlook (2024-2032)
• COVID-19 Impact on the Market
• Porter’s Five Forces Analysis
• Strategic Recommendations
• Historical, Current and Future Market Trends
• Market Drivers and Success Factors
• SWOT Analysis
• Structure of the Market
• Value Chain Analysis
• Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.

IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145